Active, not recruitingPHASE1, PHASE2NCT04661007
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
Studying Diffuse large B-cell lymphoma with chronic inflammation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Biosciences Japan GK
- Intervention
- tafasitamab(drug)
- Enrollment
- 72 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (23)
- Aichi Cancer Center Hospital, Aichi, Japan
- Chiba Cancer Center, Chiba, Japan
- National Cancer Center Hospital East, Chiba, Japan
- University of Fukui Hospital, Fukui, Japan
- National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
- Kyushu University Hospital, Fukuoka, Japan
- Kobe City Medical Center General Hospital, Hyōgo, Japan
- Tokai University Hospital, Kanagawa, Japan
- The Cancer Institute Hospital of Jfcr, Kōtoku, Japan
- Nho Kumamoto Medical Center, Kumamoto-ken, Japan
- Nho Shikoku Cancer Center, Matsuyama, Japan
- Tohoku University Hospital, Miyagi, Japan
- Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan
- Iuhw Narita Hospital, Narita, Japan
- Nho Okayama Medical Center, Okayama, Japan
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04661007 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma with chronic inflammation
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT07538180Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCLSun Yat-sen University
- RECRUITINGNCT07070648Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PETFudan University
- RECRUITINGPHASE1, PHASE2NCT06829771Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06717347A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT06687772CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell TransplantWashington University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT06760039Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCLSun Yat-sen University
- RECRUITINGPHASE2NCT06701357CR-CHOP+X in Previously Untreated DELRuijin Hospital
- RECRUITINGPHASE2NCT06664411Pola-ZR2P in Previously Untreated DLBCLNavy General Hospital, Beijing
See all trials for Diffuse large B-cell lymphoma with chronic inflammation →